Orris

Drug interactions between carbamazepine and erythromycin

Reading File
Finding Sources
Searching PubMed

carbamazepine AND erythromycin

Searching the Web

carbamazepine erythromycin interaction CYP3A4 toxicity management

Erythromycin raises carbamazepine levels, and the interaction is clinically significant. It is well documented, predictable, and starts quickly. Avoid the combination if you can.
Mechanism
  • Carbamazepine is cleared mainly by hepatic CYP3A4. It is converted to the active metabolite carbamazepine-10,11-epoxide, which also contributes to toxicity.
  • Erythromycin inhibits CYP3A4, so carbamazepine clearance falls and its plasma concentration rises. Reported levels can double or triple. A clarithromycin case report describes this pattern.
  • Carbamazepine is a CYP3A4 substrate, and erythromycin is listed alongside it among common CYP3A4 substrates. - Lippincott Illustrated Reviews: Pharmacology
  • Dermatology, 5e says the interaction "is highly predictable, develops with rapid onset, and may also occur with clarithromycin or troleandomycin." - Dermatology 2-Volume Set 5e, Macrolide Antibiotics
  • Goodman & Gilman's lists erythromycin among drugs that inhibit carbamazepine metabolism, along with propoxyphene, cimetidine, fluoxetine and isoniazid. - Goodman & Gilman's, Drug Interactions
  • Katzung's names clarithromycin, erythromycin and telithromycin as inhibitors of carbamazepine elimination. - Katzung's Basic and Clinical Pharmacology, 16th Ed, Carbamazepine
  • Tietz notes that erythromycin raises carbamazepine concentrations and supports therapeutic drug monitoring. - Tietz Textbook of Laboratory Medicine, 7th Ed, Carbamazepine
Clinical picture of toxicity
  • Toxicity can appear within days of starting the antibiotic.
  • Typical features are dizziness, vertigo, diplopia, ataxia, drowsiness, nausea, vomiting and dysarthria.
  • Severe cases can cause confusion, seizures, arrhythmia or conduction block, and coma.
  • Children and elderly patients on several drugs are at higher risk. A pediatric report and the original 1983 series both describe this.
Management
  1. Avoid the combination if possible. Use an antibiotic that does not inhibit CYP3A4. Azithromycin is generally considered a weaker CYP3A4 inhibitor, and the choice depends on the infection. This is from my own knowledge, not the library sources. Clarithromycin and troleandomycin carry the same problem.
  2. If erythromycin is unavoidable, reduce the carbamazepine dose and check serum levels closely. Check a trough level before starting and again within a few days. The usual therapeutic range is about 4 to 12 mcg/mL. The reduction needed varies by patient, so I can't give a fixed percentage.
  3. Counsel the patient to report dizziness, double vision, unsteadiness or slurred speech right away.
  4. After the antibiotic stops, inhibition wears off and carbamazepine levels fall. Re-check levels so the dose isn't left too low, which risks seizure breakthrough.
  5. Also avoid grapefruit juice. It inhibits intestinal CYP3A4 and can raise carbamazepine exposure.
Other points
  • The interaction is mostly one way. Erythromycin raises carbamazepine levels. Carbamazepine, as a CYP3A4 inducer, can also lower erythromycin levels, which may reduce antibiotic effect. This is from my own knowledge, not the sources above.
  • Erythromycin prolongs the QT interval. Combining it with other QT-prolonging drugs adds risk.
Recent evidence check: A PubMed search of the last 2 years for meta-analyses and systematic reviews found nothing that changes this. One 2025 systematic review, PMID 38676494, covers infections, seizures and drugs, but I did not read it in full.

Phenelzine in atypical depression

Reading File
Finding Sources
Finding Sources
Searching PubMed

phenelzine AND atypical depression

Searching the Web

phenelzine atypical depression efficacy vs SSRI tricyclic MAOI dietary restrictions

Reading Article

PMID: 40412292

Reading File
Phenelzine is the best-supported drug for atypical depression, and it is FDA-approved for it. The trials are small and older, and its side effects and dietary restrictions keep it from being a first-line choice.
What counts as atypical depression
  • The Columbia group defined it as reactive mood plus at least two of four features: hyperphagia, hypersomnolence, leaden paralysis, and sensitivity to rejection. - Kaplan & Sadock's Comprehensive Textbook of Psychiatry, Atypical Depression
  • Phenelzine is "FDA-approved for use in depressed patients clinically characterized as 'atypical,' 'nonendogenous,' or 'neurotic.'" - Kaplan & Sadock's, MAO-I
  • Its mechanism is irreversible inhibition of both MAO-A and MAO-B, which raises serotonin, norepinephrine and dopamine.
Evidence for efficacy
  • Versus imipramine and placebo: In the Columbia data from 269 patients, response was 72% for phenelzine, 44% for imipramine and 26% for placebo. The authors concluded that atypical patients respond poorly to tricyclics, rather than showing an enhanced response to MAOIs. Anxiety symptoms did not change response rates. - Kaplan & Sadock's
  • Versus CBT and placebo (1999, 10 weeks): Response was 58% for phenelzine, 58% for CBT and 28% for placebo. Marked side effects occurred in 92% on phenelzine and 53% on placebo. - Kaplan & Sadock's
  • Versus fluoxetine (n=40, no placebo): Response was 85% for phenelzine and 80% for fluoxetine. Remission was 70% and 80%. Neither difference was significant. Dizziness, asthenia, arthralgias, somnolence and blood pressure changes were more common with phenelzine. Tremor and weight gain were more common with fluoxetine. - Kaplan & Sadock's
  • Relapse prevention: Over a further 6 months, recurrence was 23% on continued phenelzine, 41% on continued imipramine, 47% after switching from imipramine to placebo, and 87% after switching from phenelzine to placebo. Continue phenelzine for a sustained period rather than stopping once the patient responds. - Kaplan & Sadock's
  • Tricyclics: Imipramine beats placebo in atypical features but is significantly less effective than phenelzine. - Kaplan & Sadock's, Efficacy in Subtypes
  • SSRIs: Ganong's notes that SSRIs are often ineffective in atypical depression and that MAOIs such as phenelzine and selegiline are effective. - Ganong's Review of Medical Physiology, 26th Ed. The fluoxetine trial above does not support this strongly, because it found no difference.
Recent evidence
A 2025 network meta-analysis (Fornaro et al., 21 RCTs) is the most recent synthesis. It does not overturn the textbook picture, but it adds caution.
  • On symptom change, only phenelzine beat placebo (SMD -1.31).
  • On response, phenelzine (RR 2.58) beat placebo, and it also beat imipramine (RR 1.56). Sertraline, moclobemide, fluoxetine and imipramine also beat placebo.
  • Nortriptyline did worse than the other drugs.
  • Acceptability did not differ from placebo for any drug.
  • In sensitivity analyses that excluded high-risk-of-bias trials, no drug beat placebo. Confidence in the evidence was rated low or very low.
  • The authors conclude that phenelzine "might perform better," and that high-quality trials are needed.
An older 2006 meta-analysis (Henkel), summarised in a WHO committee comment, found MAOIs better than placebo and similar to SSRIs in response rate.
Practical use
  • Place in therapy: SSRIs are generally tried first because they are safer and easier to use. Phenelzine suits patients with clear atypical features who have not responded to first-line drugs and who can follow the restrictions. Berek & Novak's says MAOIs "require dietary restrictions and can be used only in patients who are able to understand and comply with those restrictions to avoid hypertensive crises." - Berek & Novak's Gynecology, Monoamine Oxidase Inhibitors
  • Diet: Patients must avoid large amounts of tyramine-rich foods such as aged cheese and processed meats to prevent hypertensive crisis. - Ganong's
  • Interactions (my own knowledge, not from the sources above):
    • Serotonergic drugs (SSRIs, SNRIs, clomipramine, tramadol, meperidine, dextromethorphan) risk serotonin syndrome.
    • Sympathomimetics (pseudoephedrine, stimulants) risk hypertensive crisis.
    • Allow a washout of at least 2 weeks when switching to or from an MAOI, and longer after fluoxetine (about 5 weeks).
  • Common adverse effects (also my own knowledge): Orthostatic hypotension, insomnia or sedation, weight gain, sexual dysfunction and peripheral edema. Rare effects include pyridoxine-related neuropathy.
  • Dosing (also my own knowledge): Doses are often around 45 to 90 mg per day, started low and titrated. Check the local label before prescribing.
This is a shared conversation. Sign in to Orris to start your own chat.